发展一个精确的理论分解人口归因分数和应用到阿尔茨海默氏症的疾病风险分解的分解理论
Igor Akushevich1, Arseniy Yashkin1, Mikhail Kovtun1
1Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, POBox 90000, 27708, Durham, NC, USA.
Mathematical population studies
|February 20, 2026
概括
一种新的方法精确计算了人口归因分数 (PAF) 对阿尔茨海默病风险的贡献. 这种新方法应用于医疗保险数据,确定了包括抑郁症和中风在内的关键风险因素.
科学领域:
- 流行病学 流行病学
- 生物统计学 生物统计学
- 公共卫生 公共卫生
背景情况:
- 现有的人口归因分数 (PAF) 分解方法存在局限性.
- 准确估计PAF对于了解疾病负担和指导公共卫生干预至关重要.
研究的目的:
- 开发和验证用于PAF分解的数学精确方法.
- 将新方法与现有的公式进行比较 (Miettinen,Norton,Niedhammer-Chastang).
- 应用该方法来识别导致阿尔茨海默病 (AD) 风险的特定风险因素.
主要方法:
- 开发了一种新的,数学上准确的PAF分解方法.
- 将该方法应用于医疗保险数据,以估计疾病特异性PAF对AD的贡献.
- 将新方法的性能与既有公式进行了比较.
主要成果:
- 新方法适用于单个或多个数据源研究设计.
- 应用于医疗保险数据,它估计了中风 (7.2%),高血压 (6.5%),糖尿病 (4.4%),脏病 (0.9%),TBI (0.9%) 和抑郁症 (9.6%) 对AD风险的贡献.
- 诺顿公式的近似方法是先前存在的方法中最好的,但需要逐案重新估计偏差.
结论:
- 开发了一种新的,精确的PAF分解方法,克服了先前方法的局限性.
- 该方法成功地使用现实世界的数据确定了对阿尔茨海默病风险的重要贡献者.
- 进一步的研究可以扩展这种方法来分析健康差异.
更多相关视频
09:38Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:23Mechanistic Models: Compartment Models in Individual and Population Analysis
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
01:25Strategies for Assessing and Addressing Confounding
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...